Sample - Global Pharmaceutical Contract Manufacturing Market_Mordor Intelligence

8/16/2019 Sample - Global Pharmaceutical Contract Manufacturing Market_Mordor Intelligence

1/26

GLOBAL

Market Shares, Forecasts

& Trends

PH RM CEUTIC L

CONTR CT

M NUF CTURING M RKET

2015 - 2020


2/26

TABLE OF CONTENTS

1. Introduction

1.1 Research Methodology1.2 Key Findings

2. Executive Summary

3. Market Dynamics

3.1 Market Overview

3.2 Industry Value Chain Analysis

3.3 Industry Attractiveness - Porter's 5 Force Analysis

3.3.1 Bargaining Power of Suppliers

3.3.2 Bargaining Power of Consumers

3.3.3 Threat from new entrants

3.3.4 Threat from substitute products

3.3.5 Competitive rivalry within the industry

3.4 Industry Policies

3.5 Market Drivers

3.5.1 Growing Innovative drugs

3.5.2 Increasing investments in R&D

3.6 Market Restraints

3.6.1 In-house packaging

3.6.2 Capacity Utilization Issues Affecting the Profitability of CMOs

3.6.3 Increasing Lead Time & Logistics Costs

3.7 Market Opportunities

3.7.1 Huge Demand for Next-Generation Biological Therapies

4. Pharmaceutical Contract Manufacturing Market Segmentation, Forecasts and Trends - by Type

4.1 Active Pharmaceutical Ingredient (API) Manufacturing

4.2 Finished Dosage Formulation (FDF) Development & Manufacturing

4.2.1 Solid Dose Formulation


3/26

4.2.2 Liquid Dose/Semi-Solid Formulation

4.2.3 Injectable Dose Formulation

4.3 Secondary Market

5. Pharmaceutical Contract Manufacturing Market Segmentation, Forecasts and Trends - by Region

5.1 North America

5.1.1 United States

5.1.2 Canada

5.2 Europe

5.2.1 United Kingdom

5.2.2 Germany5.2.3 France

5.2.4 Italy

5.2.5 Others

5.3 Asia Pacific

5.3.1 China

5.3.2 India

5.3.3 Japan

5.3.4 Australia

5.3.5 Others

5.4 Latin America

5.4.1 Brazil

5.4.2 Mexico

5.4.3 Argentina

5.4.4 Others

5.5 Middle East and Africa

5.5.1 United Arab Emirates

5.5.2 Saudi Arabia

5.5.3 South Africa

5.5.4 Nigeria


4/26

5.5.5 Others

6. Global Vendor Market Share Analysis

6.1 Pharmaceutical CMO Vendor Market Share

6.2 API Outsourcing Vendor Market Share (Top 10 Market Players)

7. Competitive Intelligence - Company Profiles

7.1 Catalent

7.2 Recipharm

7.3 Jubilant

7.4 Patheon

7.5 Vetter7.6 Boehringer Ingelheim

7.7 Pfizer CentreSource

7.8 Aenova (Haupt)

7.9 Famar

7.10 Baxter Bio Pharma Solutions

7.11 Lonza

7.12 Biomeva

7.13 Fareva

8. Investment Analysis

8.1 Recent Mergers and Acquisitions

8.2 Investment Scenario and Opportunities

9. Future of Pharmaceutical Contract Manufacturing Market


5/26

1.1 RESEARCH METHODOLOGY

1.1.1 INTRODUCTION

The research process adopted for this entire study is a highly structured two stage process: size

estimation of the review period, and the market engineering for the forecast period of the global,

country and segment-level data that lead to the Data Generation Process (DGP) for the studied

variables. The size estimations were carried out through multiple bottom-up & top-down

approaches. The bottom-up approach includes the examining of historical revenues of key players,

studying the size of the applications, value and supply-chain analysis, end-user demand, which are

then cross-validated by secondary and primary resources. The top-down approach is an astuteresearch process where the global market sizing is carried out through the secondary research,

validated by primary industry experts.

In this report, for analyzing the future

trends for the studied market during the

forecast period, we have incorporated

rigorous statistical and econometric

methods, further scrutinized by secondary,

primary sources and by our in-house

experts supported through our extensive

data intelligence repository. The market is

studied holistically from both demand and

supply-side perspectives. This is carried outto analyze the end-user and producer

behavior patterns in the review period that affect the price, demand and consumption trends. As the

study demands analyzing the long-run nature of the market, the identification of factors influencing

the market is based on the fundamentality of the market that is studied. Through secondary and

primary research, the factors that are endogenous & exogenous in nature are identified, and they are

transformed to quantitative data through data extraction and further applied for inferential purpose.

MarketEngineering

SecondaryResearch

PrimaryResearch

EconometricModelling

Value-SupplyChain

Analysis

ExpertValidation


6/26

Study Structure

Data Extraction Process

Data Corroboration

Analysis

(Econometric ForecastModelling + Secondary

Research + Expert)Verification)

InferenceData Generation Process

(DGP) and Forecasts

Info-graphical andComprehensive

Presentation of Inferencesand Estimates

Technology /

Market

Identification

Market Definition Segmentation

Key Countries /

Regions

Mapping of Key

Players

Value / Supply

Chain Analysis

Identification of

Exogenous

Factors

Recent Market

Developments

/ Competitive

Landscaping

Validation of Market

Size Estimates

Consumer

Behaviour Analysis

Market Dynamics

Market Structure

Anal sis

Top-Down

A roach

Bottom-Up

Approach

Segment

and Region-

wise MarketSize

Forecasting

Market Share

Market StructureCompany

Profiles

Porter’s Five

Forces Analysis

Competitive

LandscapeMarket Sizing

1.1.2 RESEARCH DESIGN

Sample | Global Pharmaceutical Contract Manufacturing Market Mordor Intelligence


7/26

1.1.3 STUDY TIMELINE

Research Phase 1st Week 2nd Week 3rd Week 4th Week 5th Week

Technology / Product / Market

Identification

Internal Expert-Assessment and

Approval of the Study Content

Secondary Research

Discussion Guide

Primary Surveys

Econometric Modelling

Expert Validation

Report Writing

1.1.4 STUDY PHASES

1.1.4.1 SECONDARY RESEARCH

The first phase of the research process was an extensive secondary research and identification of

the related intelligence from our data repository on the study market. Secondary data was compiledfrom various database such as industry bodies, associations, journals, company annual reports,

white papers and research publications by recognized industry experts, paid data sources and other

published literature. Data regarding the business plans and strategies of the companies were

derived from the recent annual/investor reports of key industry players for qualitative comparisons

and analysis; financial data of these companies sourced primarily from Industry Association & Stock

Exchange Filings to maintain a standard benchmark.

SecondaryResearch

PrimaryResearch

DiscussionGuide

EconometricModelling

ExpertValidation

DataTriangulation

ReportWriting


8/26

1.1.4.2 DISCUSSION GUIDE

The next phase was preparing an exhaustive discussion guide. The primary purpose of this phase is

for extracting qualitative information regarding the market from key industry leaders. Information

collated from the discussions was further carried out for quantitative analysis. This document helps

in identifying the major market segments, market factors such as drivers, restraints, challenges, key

economic factors, interaction between the players, supply-value chain structure, bottom-up and top-

down nature of the market, competitive landscape, recent long-run and short-run strategic

developments, and market shares of the key players. This guide aids in deciding the scope and

deliverables of the study in terms of the requirement of the market.

1.1.4.3 MARKET ENGINNERING AND ECONOMETRIC MODELLING

The next phase was market engineering, which involved analysing the collected data, market

breakdown and forecasting. Macro and micro economic indicators, which were exogenous and

endogenous in nature were identified through causal and correlation analysis. They were further

analyzed with the study variable for deriving the statistical inferences on the study market. A

structural forecast model was developed in the process and the most statistically reliable model

was considered for the forecasting purpose. Such attained data points were verified by the process

of data triangulation which includes expert opinions and primary sources, to validate the numbers

and arrive at close estimates. Following data validation, the analysts begin to write the report. They

garner insights from data and forecasts, which were then drawn to visualize the entire ecosystem in

a single report.

1.1.4.4 EXPERT VALIDATION

The final phase before the report writing was the expert validation, where, the estimated and

projected values through data triangulation were cross-validated through market experts or the key

industry people. They were senior researchers, consultants, Directors, CFOs, and CEOs. The cross-

validated estimates were finally approved by the in-house experts


9/26

3. MARKET OVERVIEW

3.1 OVERVIEW

Contract manufacturing refers to outsourcing of certain production activities to third party

vendors, wherein pharmaceutical companies give the chemical formula of the drug to be

manufactured to the pharmaceutical contract manufacturers.

The market for contract manufacturing in pharmaceutical sector is one the fastest growing

markets. It is estimated that, the market will present significant opportunities in the next few

years. Contract manufacturing market is witnessing high growth as the pharmaceutical

companies are focusing more on R&D of the drugs, instead of manufacturing the formulated

drug to stay competitive in the market.

Most of the revenues of outsourcing market come from contract manufacturing, because of

its widespread adoption and increasing popularity. There has been an increase in pressure

on pharmaceutical manufacturers to cut down manufacturing cost of their products. Under

this scenario, contract manufacturing turns out to be a strategic option. Contractmanufacturing can offer benefits, such as better product quality, cost reduction, and

reduced in time to market.

The global pharmaceutical contract manufacturing market was valued at $58 billion in 2014

and is projected to reach $84 billion in 2020, at a compound annual growth rate of 6.4% over

the forecasted period. The companies in the upstream industry are undergoing restructuring

in order to focus more on R&D. On the other hand, stringent regulations on thepharmaceutical industry are compelling the companies to outsource drug manufacturing to

contract manufacturers and focus on their core business processes.

This kind of manufacturing technique also helps companies to focus more on marketing

activities and R&D by minimising the efforts and time being invested in manufacturing

process. The market is quite consolidated with big players having major share. Some of the

trend that are estimated to exert positive influence onto the market are patent expiration of


10/26

major therapeutic brands, growing demand for generic drugs, and adoption of novel

manufacturing technologies.

Solid dose formulation, by type of dose formulation, constituted more than XX% of the

overall pharmaceutical contract manufacturing market in 2014. This is attributed to lower

cost of manufacturing, patent compliance, and ease of maintenance. The segment is

expected to grow at a CAGR of 3.66% over the forecast period, while injectable dose

segment will register highest CAGR of XX.XX% over the next five years.

In 2014, the U.S. was the major market for pharmaceutical contract manufacturing,

while India is estimated to be the fastest growing market, owing to its cost competitivenessand quality manufacturing capabilities. Pharmaceutical companies are opting for less

number of vendors to take volume advantage and at the same time, reduce logistics costs.

They are increasingly relying on contract manufacturing, research, and packaging services

to fulfill their basic needs and specialized competencies. Companies are striving to minimize

costs and reduce the product development time, without affecting their efficiency and

productivity.


11/26

Competitive Rivalry between ExistingPlayers

Sustainable competitive advantage throughinnovation

Competition between online and offlinecompanies

Level of advertising expensePowerful competitive strategy

Firm concentration ratio

Degree of transparency

Threat of New Entrants

Government policy

Capital requirements

Economies of scale

Economies of product differences

Product differentiation

Switching costs or sunk costs

Access to distribution

Industry profitability (Market CAGR)

Bargaining power of Buyers

Buyer concentration to firm concentratratio

Degree of dependency upon existing chof distribution

Bargaining leverage, particularly in induwith high fixed costs

Buyer switching costs relative to firmswitching costs

Buyer information availability

Force down prices

Availability of existing substitute produ

Threat of Substitutes

Buyer propensity to substitute

Relative price performance of substitute

Buyer switching costs

Perceived level of product differentiation

Number of substitute products available in themarket

Quality depreciation

Availability of close substitute

Bargaining Power of Suppliers

Supplier switching costs relative to firmswitching costs

Degree of differentiation of inputs

Impact of inputs on cost or differentiation

Presence of substitute inputs

Strength of distribution channel

Supplier concentration to firm concentrationratio

3.3 PORTERS FIVE FORCE ANALYSIS

PORTER’S FIVE FORCES FRAMEWORK (MODEL SAMPLE)


12/26

Porter’s Five Forces model studies the five identified competitive forces that shape every

industry & every market to determine the intensity of competition, and hence the profitability

& attractiveness of the industry. The objective of growth strategy should be to adapt to

these competitive forces in a way that improves the position of the organization. This study

includes an exhaustive Porter’s Five Forces framework incorporating the factors influencing

each force to analyse the market from a microeconomic perspective.

In the study, the Porter’s five forces is analyzed considering the factors influencing each

force and quantifying the factors through primaries and quantitative analysis. The quantified

factors are further mapped to derive the impact of each force on competitive dynamics.

0

2

4

6

8

10Government policy

Capital requirements

Economies of scale

Economies of product

differences

Product differentiation

Switching costs or

sunk costs

Access to distribution

Industry profitability

(Market CAGR)

*Threat of New Entrants: The analysis for this force is carried out by considering several influencing

factors such as government policy, capital requirements, economies of scale, economies of product

differences, product differentiation, switching costs, sunk costs, access to distribution and industry

profitability. Following the quantification and rating of each factor, the data is scrutinized to derive the

impact of the force on the market dynamics on a scale of low-high-medium.

*Sample Example


13/26

3.5 MARKET DRIVERS

3.5.1 GROWING INNOVATIVE DRUGS

Pharmaceutical companies are focusing on R&D to bring in innovative and advanced drugs

into the market and thus, are outsourcing the manufacturing to third party vendors. Over the

past few years, the industry was mainly focused on growth models that are focused on

launching a cheap generic version of brand innovator drug by pharmaceutical

manufacturers. It is estimated that, the industry should focus on innovation and emerging

markets. Companies are investing heavily on innovation as the fund flow into

pharmaceutical sector is increasing because of growth in other sectors.

US Food & Drug Administration’s Centre for Drug Administration and Research (CDER) has

approved 41 novel new drugs in 2014. In the last decade, CDER has approved an average of

25 new drugs an year. The numbers in 2014 is more than the average number approved

annually compared to last decade.

Number of Innovative Drug Approvals (2005-2014)

Source: US Food and Drug Administration

There are close to 5,000 new medicines alone in the US pharmaceutical market that is

currently in development stage, which is more than in any other country in the world. The US

market is producing chemically derived drugs because of extensive R&D and clinical trials in

2022

18

2426

21

30

39

27

41

0

5

10

15

20

25

30

35

40

45

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014


14/26

both humans and animals. The innovator relies on patents and other forms of intellectual

property rights to justify the investment required for bringing a product in the market.

Several large multinationals produce the majority of innovative pharmaceuticals globally,

but they have come to rely more heavily on research performed by industry partners,

including smaller, innovative manufacturers.

3.6 MARKET RESTRAINTS

3.6.2 CAPACITY UTILIZATION ISSUES AFFECTING THE PROFITABILITY OF CMOS

Capacity constraints are still a problem in the pharmaceutical industry, and almost six in tenbio manufacturers are facing minor constraints at some stage of manufacturing. Capacity

utilization information is important for planners and investors, as they determine whether

capacity will be available for the production of pipeline drugs that may be reaching approval.

The bio-pharma segment tends to aggressively avoid unanticipated high production

demands that can create a capacity crunch. But, CMO appears to be less afflicted by

significant constraint issues than bio-therapeutic developers. Because of higher demand,

CMO capacity utilization rates have increased drastically, due to higher production levels,

and steps that CMO’s have taken to balance supply with demand.

CMOs express less overall capacity constraint concerns compared to product developers, as

they are not contracted by clients to assume tasks requiring manufacturing capacity beyond

what they can deliver. One significant factor has been improved efficiencies at the CMOs

that cannot be matched as rapidly with most developers. This is being witnessed both inupstream, and downstream operations, and is partly due to the larger number and variety of

products being manufactured by CMOs. Improvements in bioprocessing generally occur first

at CMOs. One such instance of efficiency in upstream operations being implemented at

CMOs is the increased usage of single-use bioreactors. Instead of three days to turn around

a bioreactor, the time has been reduced to a day. By eliminating time-consuming cleaning

and validation it can provide more runs per year. This has an immediate effect on capacity

utilization.


15/26

3.7 MARKET OPPORTUNITIES

3.7.1 HUGE DEMAND FOR NEXT GENERATION BIOLOGICAL THERAPIES

The initiation of regulatory procedures for entry of Biosimilars in the US market has created

a significant deal of opportunity in the CMO industry. The organizations in the European

union as well as the US are expecting a 15% rise in the demand due to biosimilars projects

during various development phases. In 2014, Novartis’ Sandoz occupied the first biosimilar

position in the US, when biosimilar drug of Amgen’s Filgastrim has been approved by FDA.

Even though there are hindrances for the biosimilar CMO success based on the value chain,

the CMOs involving in the same are seeing lucrative opportunities towards the future.Comparatively, first biosimilar in European union started with monoclonal antibody (mAb), a

Johnson & Johnson’s Remicade version and product by Celltrion and Hospira. The accepted

biosimilars llike biologics for treating growth hormones and treatment for chronic diseases

were significant among them. The companies in Europe such as Sandoz, Stada, Hospira and

Teva are dominating the biosimilar acceptance with almost 70% of the approvals. Based on

the varying differences between drug product supply and drug substance, only 10% are

utilizing the CMOs for Active Pharmaceutical Ingredient (API), whereas about 30% are using

the CMOs for fill and finish.

There exist certain products that are losing patent rights during the forecast period

including monoclonal antibodies and proteins used in the treatment of chronic diseases and

cancer. Most of these products in clinical development are distributes among the global

biopharma giants, medium sized companies and emerging competition. Biosimilars are alsoraising the hopes for the injectable CMOs, thereby augmenting the expectations of the

industry. The strategy of the CMOs towards the end of the forecast period is to develop a

plan to build expression technologies that provides a scope to deliver APIs on time as well

as to strengthen their analytical abilities. The demand for the biosimilars will create a

competitive environment in the CMO industry and stall the CMOs exiting the market due to

various constraints.


16/26

4. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

SEGMENTATION, FORECASTS, AND TRENDS - BY TYPE

Pharmaceutical Contract Manufacturing Market Forecast (2014-2020) – By Type –

$ Billion

Type 2014 2015 2016 2017 2018 2019 2020 CAGR%

Active Pharmaceutical

Ingredient (API)

XX XX XX XX XX XX XX XX.XX%

Final Dosage Formulation

(FDF)

XX XX XX XX XX XX XX 8.20%

Secondary XX XX XX XX XX XX XX XX.XX%

Total 58.00 XX XX XX XX XX XX 6.37%

Source: Mordor Intelligence Analysis

4.1 ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING

The rise in the demand for abbreviated new drug applications (ANDA) and rise in filing drug

master files (DMF) from Indian companies have fuelled the growth of API market. Most of

the companies in this industry are increasingly focusing on the development of biological

APIs, which is driving the API market. General prescription drugs have the major share in API

ingredients when compared to OTC drugs.

The market for Active Pharmaceutical Ingredient (API) was valued at $XX billion in 2014, and

is estimated to reach $XX billion by the end of 2020, at a projected CAGR of XX.XX% during

the forecast period. API was accounted for a market share of XX% of the pharmaceutical

CMO market in 2014.

Other factors driving the growth of API market includes stringent government initiatives in

healthcare sector, innovation in biologics and high potency API, and rise in the incidence of

cancer and age-related diseases. However, strict European regulatory policies might hinder

the growth in API market. Captive manufacturers are currently leading the API market;


17/26

however, it is slowly losing the market share to contract manufacturers towards the end of

forecast period. This is due to the complex and expensive in-house manufacturing of API

and rise in competition from emerging players in this industry.

North America is dominating the API market due to its wide reach in R&D including

therapies and drugs. High growth in this region is attributed to increasing demand for

biologics and specialty drugs, increasing government focus on generic drugs, and

technological developments. The Asia-Pacific region is estimated to grow at the highest rate

and is expected to be the most lucrative market during the forecast period. The availability

of generic manufacturers is significantly driving growth in this region. Additionally,

increasing incidence of cancer and increasing number of contract manufacturing

organizations are also driving growth in this region. The major trend in this market is

development of High-Potency API (HPAPI), which is influenced by the innovation in

oncology, clinical pharmacology, and rise in demand for hormonal therapeutics.

Active Pharmaceutical Ingredient Market Forecast (2014-2020) – $ billion

Source: Mordor Intelligence Analysis

2014 2015 2016 2017 2018 2019 2020

SAMPLE FIGURE


18/26

5. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

SEGMENTATION, FORECASTS AND TRENDS - BY REGION

One of the significant changes outsourcing space has undergone is the evolution of

strategic contract manufacturing. Traditionally, the contract manufacturing involved a

vendor–customer equation. However, recently this traditional concept is being phased out,

and contract manufacturers are forming alliance with drug formulating companies for

greater profit margins. CMOs have become the primary choice for pharmaceutical

companies, attributing to intensive capital requirement and complexity of manufacturing.

Biopharmaceutical manufacturing is turning out to be a huge opportunity for CMOs.

Especially in developed markets such as North America and Europe, CMO is growing at

almost twice the growth rate of the pharmaceutical industry. One major setback for CMO

industry is the conversion of contract manufacturing capacity to captive/in-house capacity.

This can occur due to either the acquisition of facilities and companies, or just by a

company no longer offering their additional capacity to the contract market. Even though

these acquisitions have marginal impact, acquisitions such as Pfizer’s acquisition of Hospira

could be disruptive. Large global companies outsource only about 1/3 rd of their production

to CMOs, and with additional investments to expand the facilities, CMOs globally are going

to face a challenge.

The global market for pharmaceutical CMO was valued at $58 billion in 2014 and is

estimated to reach $84 billion by 2020, growing at a CAGR of 6.37%. In 2014, North America

held the major share of the market with a share of XX%, followed by XX and XX with sharesof XX% and XX% respectively. In terms of growth, Asia Pacific is estimated to witness the

highest growth, due to the presence of emerging markets such as China, India and Japan.

The region is projected to grow at a CAGR of XX% over the forecast period 2014-2020,

followed by XX and XX.


19/26

Global Pharmaceutical CMO Market - Forecast ($ billions)

Pharmaceutical CMO Market Share by Region (2014

Source: Mordor Intelligence

2014 2015 2016 2017 2018 2019 2020

North America Europe APAC Latin America Middle East & Africa

SAMPLE FIGURE

North America

Europe

APAC

Latin America

Middle East & Africa

SAMPLE FIGURE


20/26

7. COMPANY PROFILES

7.4 PATHEON

7.4.1 COMPANY OVERVIEW

Founded in 1974, Patheon Inc. is a pharmaceutical company, with its corporate head offices

in Durham, North Carolina with 4,000 employees. Patheon is a contract development and

manufacturing services providing products for pharmaceutical companies. Patheon

competitors in the contract manufacturing include Baxter and cardinal health, which are

based in USA.

Patheon is transforming the way pharmaceuticals are made with a simplified, end-to-end

supply chain solution for pharmaceutical and biopharmaceutical companies of all sizes.

Drug substances and drug products, Development and manufacturing, Small and large

molecules, Sterile, oral solid and softgel dosage forms are the services offered. Patheon

offers a comprehensive range of services spanning all phases and scales that is wider and

deeper than that of any other CDMO.

Patheon gives even the smallest pharma and biotech companies’ instant access to a fully

integrated global network of facilities across North America, Europe, Asia and Australia. This

includes eleven for commercial-scale finished dosage forms, four for API process

development and manufacturing, four for biologics, and ten for pharmaceutical

development.

7.4.2 PRODUCT & SERVICES

Products Description

Oral Solids With more than 40 years of experience and a remarkable range of

conventional and specialized oral solid dose form options, the company offers

to expand options with innovative combinations of these forms and a variety

of controlled-release technologies. All these choices are executed with the


21/26

expansive scientific resources and expertise to rapidly develop successful

formulations for even the most complex APIs including highly potent

compounds and controlled substances.

Steriles The company offers extensive sterile pharmaceutical product development

capabilities, including world-class expertise in lyophilization. With Patheon

there is access to state-of-the-art commercial-scale GMP manufacturing for

prefilled syringes and cartridges. Ready-to-use dosage forms enable self

administration of parenterals that once required a clinical visit. As the

healthcare industry seeks to move treatments into the home, Patheon is

investing in capabilities that will keep you ahead in the evolving marketplace.

Softgels Most patients, especially children and seniors, prefer softgels. With Patheon,

there is access to a broad palette of shapes, sizes and colors, as well as

unique chewable, topical and suppository options.

7.4.3 COMPANY FINANCIALS (IN US$ MILLION)

Year Total revenue Gross profit Operating income

2013 1023.1 249.1 33.9

2012 749.1 159.3 36.9

7.4.4 RECENT DEVELOPMENTS

Date Recent development

September

2015

Patheon unveiled its new brand identity, reflecting the company’s leadership

position in the pharmaceutical services industry, and the difference it makes in

the lives of patients. The new brand positioning centers around an updated

brand promise based on the fundamental belief that the world would be a

healthier place if tomorrow’s medicines were made available today.

July 2015 Ardian Acquires Exclusive Synthesis (ES) And Maleic Anhydride Intermediates

& Specialties (IM) Business From DPx Holdings B.V.


22/26

July 2015 LIVIA Group, a German-based industrial holding, has entered into an

agreement to acquire the Capua manufacturing facility and associated

employees from Patheon, a leading global provider of outsourced contract

development and manufacturing (CDMO) services for the pharma and

biopharma industries.

March

2014

Patheon has merged with royal DSMs pharmaceutical products business to

form DPx in a $2.65bn (€1.9bn) deal.


23/26

SOME OF OUR CLIENT


24/26

Mordor Intelligence

SOME OF OUR CLIE


25/26

DISCLAIMER

Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable

market information, are provided to a select group of customers in response to orders. Our customers

acknowledge when ordering that Mordor Intelligence strategic analysis services are for our customers’ internal

use and not for general publication or disclosure to third parties.

Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor

Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users.

No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written

permission. Reproduction and/or transmission in any form and by any means including photocopying,

mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.

ABOUT US

Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research

insights for business success.

Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing,

Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one

common trait - we love data and we love providing solutions to clients using that data even more. Seeing your

business flourish based on our solutions and strategy is what we love the most.

For information regarding permissions and sales, please contact: [email protected]

mailto:[email protected]:[email protected]


26/26

We can add to your revenues without being your cost.

Date post:	05-Jul-2018
Category:	Documents
Upload:	shahid-shoaib
View:	219 times
Download:	0 times

Sample - Global Pharmaceutical Contract Manufacturing Market_Mordor Intelligence

Documents